Dietrich Horlein

Title: Dietrich Horlein: Innovator in Biochemical Therapeutics

Introduction

Dietrich Horlein is a notable inventor based in Wuppertal, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of therapeutic agents. With a total of 4 patents to his name, Horlein's work focuses on innovative solutions for medical applications.

Latest Patents

Horlein's latest patents include groundbreaking research on variants of bovine pancreatic trypsin inhibitor produced by recombinant DNA technology. One of his notable inventions involves peptides that have sequences of bovine pancreatic trypsin inhibitor (aprotinin) with specific amino acid replacements. These peptides are designed to serve as therapeutic agents in diseases associated with excessive proteinases. Another significant patent details a genetically engineered aprotinin variant, which includes a deletion of proline at position 2 or an addition of alanine-(-2)-glutamine-(-1). This modified aprotinin is intended for use as an active ingredient in medicaments.

Career Highlights

Dietrich Horlein is associated with Bayer Aktiengesellschaft, a leading global company in the pharmaceutical and life sciences sector. His work at Bayer has allowed him to explore and develop innovative therapeutic solutions that address critical health challenges.

Collaborations

Throughout his career, Horlein has collaborated with esteemed colleagues such as Wolfgang Bruns and Ernst-August Auerswald. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.

Conclusion

Dietrich Horlein's contributions to biochemistry and therapeutic innovations underscore his role as a leading inventor in the field. His patents reflect a commitment to advancing medical science and improving patient outcomes.